Vaxcyte Initiates Study on VAX-31 for Adults Over 50 with Prior Pneumococcal Vaccination
Vaxcyte, Inc. is conducting a study to assess the safety, tolerability, and immunogenicity of VAX-31 in older adults.
Asset / Drug
Drug and asset intelligence for VAX-31 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Vaccine
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.